# Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study

> **NCT07132463** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 154 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **RADIATION:** Long-course chemoradiotherapy
- **DRUG:** Tislelizumab combined with the CAPOX regimen
- **DRUG:** CAPOX regimen

## Key facts

- **NCT ID:** NCT07132463
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2027-12
- **Final completion:** 2030-12
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07132463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07132463, "Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT07132463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*